Johnson & Johnson 13F institutional holdings

Johnson & Johnson reported 15 holdings worth $798.7M for the period ended June 30, 2026.

Johnson & Johnson's Q1 2026 13F filing reveals a diverse portfolio of investments, with a significant focus on biotechnology and healthcare innovation.

Johnson & Johnson filed an amended 13F-HR report, restating its equity holdings for the quarter ended December 31, 2025, totaling $555 million.

Johnson & Johnson filed an amended 13F report, restating its institutional investment holdings totaling over $503 million for the quarter ended September 30, 2025.

Johnson & Johnson's latest 13F filing reveals its investment portfolio for the quarter ended December 31, 2025, totaling over $554 million across 17 companies.

Johnson & Johnson filed its Form 13F-HR, revealing its equity holdings totaling over $503 million as of September 30, 2025.

Johnson & Johnson filed its Q2 2025 Form 13F-HR, revealing a total equity portfolio value of $334.1 million across 20 distinct holdings.

Johnson & Johnson's Q1 2025 13F filing discloses its holdings, with a total value of approximately $341.9 million, primarily focused on biotech companies.

Johnson & Johnson's latest 13F filing discloses its holdings as of December 31, 2024, showcasing a substantial investment portfolio primarily focused on the biotechnology sector.

Johnson & Johnson's latest 13F filing reveals a diverse portfolio of equity holdings totaling over $427 million as of September 30, 2024.

Johnson & Johnson's latest 13F filing discloses its holdings as of June 30, 2024, revealing significant investments in various biotech and pharmaceutical companies.

Johnson & Johnson's Q1 2024 13F filing reveals a $4.4 billion portfolio with substantial holdings in biotech and pharmaceutical companies.